06-10-2022, 09:30 AM
(06-09-2022, 07:23 AM)BFritz21 Wrote: A few problems with your post.
First, a cure would be a one-time cost, whereas treatments are on an on-going expense.
Second, it would be hard to patent a cure, so companies would just keep making it available at a cheaper cost or come up with their own cheaper cure.
“ US patents on Harvoni and Epclusa do not expire until 2030 and 2032”
https://www.pharmaceutical-technology.com/comment/gilead-hep-c-generercs/
